Page 4 - Generation Bio News Today

TODAY’S GAME PLAN: from the trading desk, this is not research DATA/HEADLINES 8:30ET Weekly Jobless Claims, Philly Fed; 9:00ET Fed’s Jefferson speaks; 10:00ET Existing Home Sales, Leading Index; 12:00ET Fed’s Powell speaks; 1:20ET Fed’s Goolsbee speaks; 1:30ET Fed’s Barr speaks; 4:00ET Fed’s Bostic speaks; 5:30ET Fed’s Harker speaks; 6:40ET Fed’s Logan speaks TODAY’S HIGHLIGHTS: Israeli

-- Generation Bio has an average rating of outperform and price targets ranging from $5.97 to $16, according to analysts polled by Capital IQ. Price: 2.4, Change: -0.01, Percent Change: -0.41 ...

– Immune-quiet DNA (iqDNA) is a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection in both mice and non-human primates...

– Immune-quiet DNA is a novel variant of closed-ended DNA that evades host innate immune detection in both mice and non-human primates with a systemic cytokine profile and tolerability comparable...

Generation Bio Co. announced the development of a proprietary, novel DNA called immune-quiet DNA . iqDNA is an optimized variant of the companys closed-ended DNA that upon systemic administration...

Generation Bio Co. (NASDAQ:GBIO – Get Free Report) has been given an average rating of “Moderate Buy” by the six analysts that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price target […]

Avidity Biosciences (NASDAQ:RNA – Get Free Report) and Generation Bio (NASDAQ:GBIO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership. Analyst Recommendations This is a summary of […]

CAMBRIDGE, Mass., Sept. 19, 2023 -- Generation Bio Co. , a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough,...

Shares of Generation Bio Co. (NASDAQ:GBIO – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price […]

Needham & Company LLC reaffirmed their buy rating on shares of Generation Bio (NASDAQ:GBIO – Free Report) in a report published on Thursday, Benzinga reports. They currently have a $14.00 target price on the stock. Separately, Wedbush reissued an outperform rating and issued a $11.00 price objective on shares of Generation Bio in a research […]